NJ State Employees Deferred Compensation Plan maintained its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 40,000 shares of the biotechnology company’s stock at the end of the second quarter. NJ State Employees Deferred Compensation Plan’s holdings in Ironwood Pharmaceuticals were worth $755,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Capital Impact Advisors LLC increased its stake in Ironwood Pharmaceuticals by 266.9% in the first quarter. Capital Impact Advisors LLC now owns 75,749 shares of the biotechnology company’s stock worth $1,292,000 after buying an additional 55,103 shares during the last quarter. American Century Companies Inc. acquired a new stake in Ironwood Pharmaceuticals during the first quarter worth approximately $1,879,000. Parametric Portfolio Associates LLC increased its stake in Ironwood Pharmaceuticals by 3.7% in the first quarter. Parametric Portfolio Associates LLC now owns 80,693 shares of the biotechnology company’s stock worth $1,377,000 after buying an additional 2,913 shares during the last quarter. Parametrica Management Ltd acquired a new stake in Ironwood Pharmaceuticals during the first quarter worth approximately $258,000. Finally, Karp Capital Management Corp acquired a new stake in Ironwood Pharmaceuticals during the first quarter worth approximately $201,000. Institutional investors and hedge funds own 98.16% of the company’s stock.

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) opened at 15.48 on Monday. Ironwood Pharmaceuticals, Inc. has a 12-month low of $12.48 and a 12-month high of $19.94. The stock’s 50 day moving average is $18.36 and its 200-day moving average is $17.14. The firm’s market cap is $2.30 billion.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.05. The firm had revenue of $65.10 million during the quarter, compared to analyst estimates of $70 million. Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The business’s revenue was up 19.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.16) earnings per share. On average, analysts anticipate that Ironwood Pharmaceuticals, Inc. will post ($0.91) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/07/nj-state-employees-deferred-compensation-plan-holds-position-in-ironwood-pharmaceuticals-inc-irwd.html.

IRWD has been the topic of a number of research reports. Wells Fargo & Company set a $19.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, July 22nd. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Cowen and Company set a $20.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, April 13th. Mizuho reiterated a “buy” rating and issued a $23.00 target price (up from $22.00) on shares of Ironwood Pharmaceuticals in a report on Wednesday, August 2nd. Finally, Wood & Company downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Friday, July 21st. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $18.00.

In related news, insider Thomas A. Mccourt sold 30,000 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $18.20, for a total value of $546,000.00. Following the sale, the insider now directly owns 30,000 shares in the company, valued at approximately $546,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Halley E. Gilbert sold 35,000 shares of the stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $19.75, for a total transaction of $691,250.00. Following the completion of the sale, the insider now owns 35,000 shares in the company, valued at $691,250. The disclosure for this sale can be found here. Company insiders own 7.63% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.